Disorders Involving Abnormal Coagulation

Section 5 - Disorders Involving Abnormal Coagulation

Published online by Cambridge University Press: 15 June 2018

Edited by

Louis Caplan and

José Biller

Show author details

Louis Caplan: Affiliation:
Beth Israel-Deaconess Medical Center, Boston
José Biller: Affiliation:
Loyola University Stritch School of Medicine, Chicago

Book contents

Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Type: Chapter
Information: Uncommon Causes of Stroke , pp. 305 - 358

DOI: https://doi.org/10.1017/9781316551684 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2018

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Agnelli, G., Buller, H. R, Cohen, A., et al. 2013 Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med, 368, 799–808.CrossRef Google Scholar

Alarcon-Segovia, D., Deleze, M., and Oria, C. V. 1989. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus: A prospective analysis of 500 consecutive patients. Medicine, 68, 353–65.Google Scholar

Ameri, A. and Bousser, M. G. 1992. Cerebral venous thrombosis. Neurol Clin, 10, 87–111.CrossRef Google Scholar PubMed

Andreoli, L., Chighizola, C. B., Banzato, A., et al. 2013. Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: A critical review of the literature. Arthritis Care Res, 65, 1869–73.CrossRef Google Scholar PubMed

Antiphospholipid Antibodies in Stroke Study (APASS) Group. 1990. Clinical and laboratory findings in patients with antiphospholipid antibodies and cerebral ischemia. Stroke, 21, 1268–73.Google Scholar

Arnout, I. 1996. The pathogenesis of antiphospholipid antibody syndrome: Hypothesis based on parallelisms with heparin-induced thrombocytopenia. Thromb Haemost, 75, 536–41.Google Scholar PubMed

Arnout, J. and Vermylen, I. 1998. Mechanism of action of beta-2-glycoprotein-1-dependent lupus anticoagulants. Lupus, 7, S23–8.Google Scholar PubMed

Arnaud, L., Mathian, A., Ruffatti, A., et al. 2014. Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-anaylsis. Autoimmunity Reviews, 13, 281–91.Google Scholar

Asherson, R.A. 1992. The catastrophic antiphospholipid syndrome. J Rheumatol, 19, 506–12.Google Scholar

Asherson, R. and Cervera, R. 2003. Catastrophic antiphospholipid syndrome. Rheumatol Rep, 5, 395–400.CrossRef Google Scholar PubMed

Atsumi, T., Ieko, M., Bertolaccini, M. L., et al. 2000. Association of autoantibodies against the phosphatidylserine–prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum, 43, 1982–93.Google Scholar

Bauer, K. A. 2013. Pros and cons of new oral anticoagulants. Hematology, 2013, 464–70.CrossRef Google Scholar PubMed

Bauersachs, R., Berkowitz, S. D., Brenner, B., et al. 2010. Oral rivaroxaban for symptomatic venous thromboembolism (and supplementary appendix). N Engl J Med, 363, 2499–510.Google Scholar

Belvís, R., Santamaría, A., Martí-Fàbregas, J., et al. 2007. Patent foramen ovale and prothrombotic markers in young stroke patients. Blood Coagul Fibrinolysis, 18, 537–42.Google Scholar

Bertolaccini, M. L., Amengual, O., Andreoli, L., et al. 2014. 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmunity Rev, 13, 917–30.Google Scholar

Bottin, L., Frances, C., de Zuttere, D., et al. 2015. Strokes in Sneddon syndrome without antiphospholipid antibodies. Ann Neurol, 77, 817–29.Google Scholar

Boles, J. and Mackman, N. 2010. Role of tissue factor in thrombosis in antiphospholipid antibody syndrome. Lupus, 19, 370–78.Google Scholar

Brey, R. L. 2004. Management of the neurological manifestations of APS: What do the trials tell us? Thromb Res, 114, 489–99.Google Scholar

Brey, R. L., Hart, R. G., Sherman, D. G., and Tegeler, C. T. 1990. Antiphospholipid antibodies and cerebral ischemia in young people. Neurology, 40, 1190–6.Google Scholar

Büller, H. R., Décousus, H., Grosso, M. A., et al. 2013. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med, 369, 1406–15.Google Scholar

Campbell, A. L., Pierangeli, S. S., Wellhausen, S., and Harris, E. N. 1995. Comparison of the effects of anticardiolipin antibodies from patients with the antiphospholipid antibody syndrome and with syphilis on platelet activation and aggregation. Thromb Haemost, 73, 529–34.Google Scholar PubMed

Carhuapoma, J. R., Mitsias, R., and Levine, S. R. 1997. Cerebral venous thrombosis and anticardiolipin antibodies. Neurology, 28, 2363–9.Google Scholar

Casciola-Rosen, L., Rosen, A., Petri, M., and Schlissel, M. 1996. Surface blebs on apoptotic cells are sites of enhanced procoagulant activity implications for coagulation events and antigenic spread in systemic lupus erythematosus. Proc Natl Acad Sci USA, 93, 1624–9.CrossRef Google Scholar PubMed

Cervera, R., Piette, J. C., Font, J., et al. 2002. Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum, 46, 1019–27.Google Scholar

Cervera, R., Khamashta, M. A., Font, J., et al. 2003. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: A comparison of early and late manifestations in a cohort of 1000 patients. Medicine, 82, 299–308.Google Scholar

Cervera, R., Serrano, R., Pons-Estel, G. J. et al. 2015. Morbidity and mortality in the antiphospholiid syndrome during a 10-year period: A multicenter prospective study of 1000 patients. Ann Rheum Dis, 74, 1011–18.Google Scholar

Cesbron, J. Y., Amouyel, R., and Masy, E. 1997. Anticardiolipin antibodies and physical disability in the elderly. Ann Intern Med, 126, 1003.Google Scholar

Chapman, J., Abu-Katash, M., Inzelberg, R., et al. 2002. Prevalence and clinical features of dementia associated with the antiphospholipid syndrome and circulating anticoagulants. J Neurol Sci, 203–204, 81–4.Google Scholar

Chaturvedi, S., Jin, Z., Homma, S., et al., on behalf of the PICSS–APASS investigators. 2009. Patent foramen ovale, cardiac valve thickening, and antiphospholipid antibodies as risk factors for subsequent vascular events. The PICSS–APASS study. Stroke, 40, 2337–42.Google Scholar

Chinnery, P. E, Shaw, P. I., Ince, P. G., Jackson, G. H., and Bishop, R. I. 1997. Fulminant encephalopathy due to the catastrophic primary antiphospholipid syndrome. J Neurol Neurosurg Psychiatry, 62, 300–1.Google Scholar

Ciocca, R. G., Choi, J., and Graham, A. M. 1995. Antiphospholipid antibodies lead to increased risk in cardiovascular surgery. Am J Surg, 170, 198–200.Google Scholar

Cojocaru, I. M., Cojocaru, M., Burcin, C., et al. 2007. Evaluation of antiphospholipid antibodies in young women with ischemic stroke. Romanian J Int Med, 45, 201–4.Google Scholar

Crowther, M. A., Ginsberg, J. S., Julian, J., et al. 2003. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. [See comment] [erratum appears in N Engl J Med, 2003 Dec 25; 349, 2577]. N Engl J Med, 349, 1133–8.Google Scholar

de Moerloose, P., Boehlen, E., and Reber, G. 1997. Prevalence of anticardiolipin and antinuclear antibodies in an elderly hospitalized population and mortality after a 6-year follow-up. Age Aging, 27, 319–21.Google Scholar

Del Papa, N., Guidali, L., Sala, A., et al. 1997a. Endothelial cells as target for antiphospholipid antibodies. Arthritis Rheum, 40, 551–61.Google Scholar PubMed

Del Papa, N., Raschi, E., Catelli, L., et al. 1997. Endothelial cells as a target for antiphospholipid antibodies: Role of anti-beta-2-glycoprotein 1 antibodies. Am J Reprod Immunol, 38, 212–7.Google Scholar

Deschiens, M. A., Conard, J., Horellou, M. H., et al. 1996. Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous sinus thrombosis. Stroke, 27, 1724–30.Google Scholar

Drouvalakis, K. A. and Buchanan, T. T. C. 1998. Phospholipid specificity of autoimmune and drug induced lupus anticoagulants: Association of phos-phatidylethanolamine reactivity with thrombosis in autoimmune disease. J Rheumatol, 25, 290–5.Google Scholar

Erkan, D., Lockshin, M. D., and APS ACTION members. 2012. APS ACTION–Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking. Lupus, 21, 695–98.Google Scholar

Erkan, D., Aguiar, C. L., Andrade, D., et al., 2014. 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome treatment trends. Autoimmunity Rev, 13, 685–96.Google Scholar

Filippidis, E., Kapsalaki, G., Patramani, K., et al. 2009. Cerebral venous sinus thrombosis: Review of the demographics, pathophysiology, current diagnosis, and treatment. Neurosurgical Focus, 27, E3.Google Scholar

Galli, M., Comfurius, P., Maassen, C, et al. 1990. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet, 335, 1544–7.Google Scholar

Gharavi, A. E. and Pierangeli, S. S. 1998. Origin of antiphospholipid antibodies: Induction of aPL by viral peptides. Lupus, 7, S52–4.Google Scholar

Gharavi, A. E., Tang, H., Gharavi, E. E., Wilson, W. A., and Espinoza, L. R. 1995. Induction of aPL by immunization with a 15 amino acid peptide. Arthritis Rheum, 38, S296.Google Scholar

Gharavi, A. E., Tang, H., Gharavi, E. E., Espinoza, L. R., and Wilson, W. A. 1996. Induction of antiphospholipid antibodies by immunization with a viral peptide. Arthritis Rheum, 39, S319.Google Scholar

Hachulla, E., et al. 1998. Cerebral magnetic resonance imaging in patients with or without antiphospholipid antibodies. Lupus, 7, 124–31.Google Scholar

Hudson, M., Herr, A. L., Rauch, J., et al. 2003. The presence of multiple prothrombotic risk factors is associated with a higher risk of thrombosis in individuals with anticardiolipin antibodies. J Rheumatol, 30, 2385–91.Google Scholar

Hughes, G. R. V. 1983. Thrombosis, abortion, cerebral disease and lupus anticoagulant. Br Med J, 187, 1088–91.Google Scholar

Jacobson, M. W., Rappaport, L. J., Keenan, R. A., et al. 1999. Neuropsychological deficits associated with antiphospholipid antibodies. J Clin Exp Neuropsychol, 21, 251–64.Google Scholar

Janardhan, V., Wolf, P. A., Kase, C. S., et al. 2004. Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attack: the Framingham cohort and offspring study. Stroke, 35, 736–41.Google Scholar

Kalashnikova, L. A., Nasonov, E. L., Kushekbaeva, A. E., and Gracheva, L. A. 1990. Anticardiolipin antibodies in Sneddon’s syndrome. Neurology, 40, 464–7.Google Scholar

Khamashta, M. A., Cuadrado, M. J., Mujic, F., et al. 1995. The management of thrombosis in the antiphospholipid antibody syndrome. N Engl J Med, 332, 993–7.Google Scholar

Klemp, P., Cooper, R. C, Strauss, F. J., et al. 1988. Anticardiolipin antibodies in ischemic heart disease. Clin Exp Immunol, 74, 254–7.Google Scholar

Krnic-Barrie, S., Reister, O., Connor, C., et al. 1997. A retrospective review of 61 patients with antiphospholipid syndrome. Arch Intern Med, 157, 2101–8.Google Scholar

Labarca, J. A., Rabaggliati, R. M., Radrigan, F. J., et al. 1997. Antiphospholipid syndrome associated with cytomegalovirus infection: case report and review of the literature. Clin Infect Dis 24, 197–200.CrossRef Google Scholar

Law, G., Magder, L., Fang, H., et al., 2014. Hydroxychloroquine reduces thrombosis (both arterial and venous) in systemic lupus erythematosus, particularly in antiphospholipid positive patients. Annals of the Rheumatic Diseases, 71, 547.Google Scholar

Levine, S. R., Brey, R. L., Salowich-Palm, L., Sawaya, K. L., and Havstad, S. 1993. Antiphospholipid antibody associated stroke: Prospective assessment of recurrent event risk. Stroke, 24, 188.Google Scholar

Levine, S. R., Brey, R. L., Sawaya, K. L., et al. 1995. Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome. Ann Neurol, 38, 119–24.Google Scholar

Levine, S. R., Brey, R. L., Tilley, B. C, et al. 2004. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA, 291, 576–84.Google Scholar

Levy, R. A., Awad, E., Olivera, J., and Porto, L. C. 1998. Placental pathology in antiphospholipid syndrome. Lupus, 7, S81–5.CrossRef Google Scholar PubMed

Loizou, S., McCrea, J. D., Rudge, A. C, et al. 1985. Measurement of anticardiolipin antibodies by an enzyme linked immunosorbent assay (ELISA): Standardization and quantitation of results. Clin Exp Immunol, 62, 738–45.Google Scholar

Lopez, L. R., Dier, K. J., Lopez, D., Merrill, J. T., Fink, C. A. 2004. Beta-2-glycoprotein 1 and antiphosphatidylserine antibodies are predictors of arterial thrombosis in patients with antiphospholipid antibody syndrome. Am J Clin Pathol 121, 142–9.Google Scholar

Marlar, R. A. and Neumann, A. 1990. Neonatal purpura fulminans due to homozygous protein C or protein S deficiencies. Semin Thromb Hemost, 16, 299–309.Google Scholar

McIntyre, J. A., Wagenknecht, D. R., and Waxman, D. W. 2003. Frequency and specificities of antiphospholipid antibodies in volunteer blood donors. Immunobiol, 207, 59–63.Google Scholar

McNeil, H. P., Simpson, R. J., Chesterman, C. N., and Krilis, S. A. 1990. Antiphospholipid antibodies are directed to a complex antigen that includes a lipid-binding inhibitor of coagulation: β₂-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA, 87, 4120–4.CrossRef Google Scholar PubMed

Meroni, P. L., Del Papa, N., Raschi, E., et al. 1998. β₂ glycoprotein 1 as a co-factor for antiphospholipid reactivity with endothelial cells. Lupus, 7, S44–7.Google Scholar

Miyakis, S., Lockshin, M. D., Atsumi, T., et al. 2006. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost, 4, 295–306.Google Scholar

Molad, Y., Sidi, Y., Gornish, M., et al. 1992. Lupus anticoagulant: Correlation with magnetic resonance imaging of brain lesions. J Rheumatol, 19, 556–61.Google Scholar

Monroe, D. M. and Key, N. S. 2007. The tissue factor–factor VIIa complex: Procoagulant activity, regulation, and multitasking. J Thromb Haemost, 5, 1097–105.Google Scholar

Mosek, A., Yust, L., Trêves, T. A., et al. 2000 Dementia and antiphospholipid antibodies. Dement Geriatr Cogn Disord, 11, 36–8.Google Scholar

Nencini, R., Baruffi, M. C., Abbate, R., et al. 1992. Lupus anticoagulant and anticardiolipin antibodies in young adults with cerebral ischemia. Stroke, 23, 189–93.Google Scholar

Neville, C., Ruach, J., Kassis, J., et al. 2003. Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies. Thromb Haemost, 90, 108–15.Google Scholar

Nojima, J., Suehisa, E., Akita, N., et al. 1997. Risk of arterial thrombosis in patients with anticardiolipin antibodies and lupus anticoagulant. Br J Haematol, 96, 447–50.Google Scholar

Nojima, J., Masuda, Y., Iwatani, Y., et al. 2008. Tissue factor expression on monocytes induced by antiphospholipid antibodies as a strong risk factor for thromboembolic complications in SLE patients. Biochem Biophys Res Commun, 365, 195–200.Google Scholar

Otomo, K., Atsumi, T., Amengual, O., et al. 2012. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheumatism, 64, 504–12.Google Scholar

Pengo, V., Ruffatti, A., Legnani, C., et al. 2011. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: A multicenter prospective study. Thrombosis Hemostasis, 118, 4717–18.Google Scholar

Pezzini, A., Grassi, M., Lodigiani, C., et al. 2014. Predictors of long-term recurrent vascular events after ischemic stroke at young age. The Italian project on stroke in young adults. Circulation, 129, 1668–76.Google Scholar

Pierangeli, S. S., Girardi, G., Vega-Ostertag, M., et al. 2005. Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia. Arthritis Rheum, 52, 2120–4.Google Scholar

Provenzale, J. M., Heinz, E. R., Ortel, T. L., et al. 1994. Antiphospholipid antibodies in patients without systemic lupus erythematosus: Neuroradiologic findings. Radiology, 192, 531–7.Google Scholar

Rand, J. H., Wu, X. X., Andree, H. A., et al. 1997. Pregnancy loss in the antiphospholipid antibody syndrome: A possible thrombogenic mechanism. N Engl J Med, 337, 154–60.Google Scholar

Rand, J. H., Wu, X. X., Quinn, A. S., et al. 2008. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody–beta2-glycoprotein I complexes to phospholipid bilayers. Blood, 112, 1687–95.Google Scholar

Rosove, M. H. and Brewer, P. M. C. 1992. Antiphospholipid thrombosis: Clinical course after the first thrombotic event in 70 patients. Ann Intern Med, 117, 303–8.Google Scholar

Roubey, R. A. S. 1998. Mechanisms of autoantibody-mediated thrombosis. Lupus, 7, S114–9.Google Scholar

Saidi, S., Mahjoub, T., and Almawi, W. Y. 2009. Lupus anticoagulants and antiphospholipid antibodies as risk factors for a first episode of ischemic stroke. J Thromb Haemost, 7, 1075–80.Google Scholar

Sailer, M., Burchert, W., Ehrenheim, C., et al. 1997. Positron emission tomography and magnetic resonance imaging for cerebral involvement in patients with systemic lupus erythematosus. J Neurol, 244, 186–93.Google Scholar

Schmidt, R., Auer-Grumbach, P., Fazekas, F., Offenbacher, H., and Kapeller, R. 1995. Anticardiolipin antibodies in normal subjects. Neuropsychological correlates and MRI findings. Stroke, 26, 749–54.Google Scholar

Schmidt-Tanguy, A., Voswinkel, J., Henrion, D., Subra, J., Loufrani, L., et al. 2013. Anti- thrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients. J Thromb Haemost, 11, 1927–9.Google Scholar

Schulman, S., Kearon, C., Kakkar, A. K., et al. 2009. Dabigatran versus warfarin for the treatment of acute venous thromboembolism. N Engl Med, 361, 2341–52.Google Scholar

Sciascia, S., Cosseddu, D., Montaruli, B. et al. 2011. Risk scale for the diagnosis of antiphospholipid syndrome. Ann Rheum Dis, 70, 1517–18.Google Scholar

Sciascia, S., Sanna, G., Murru, V., et al. 2013. GAPPS: The global anti-phospholipid syndrome score. Rheumatology, 52, 1397–403.Google Scholar

Sciascia, S., Sanna, G., Khamashta, M. A., et al. 2015. The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: A systematic review. Ann Theum Dis, 74, 2028–33.Google Scholar PubMed

Shah, N. M., Khamashta, M. A., Atsumi, T., and Hughes, G. R. V. 1998. Outcome of patients with anticardiolipin antibodies: A 10 year follow-up of 52 patients. Lupus, 7, 3–6.Google Scholar

Shi, T., Iverson, G. M., Qi, J. C., et al. 2004. Beta 2-glycoprotein I binds factor XI and inhibits its activation by thrombin and factor XIIa: Loss of inhibition by clipped beta 2-glycoprotein I. Proc Natl Acad Sci U S A, 101, 3939 –44.Google Scholar

Sneddon, I. B. 1965. Cerebral vascular lesions in livedo reticularis. Br J Dermatol, 77, 180–5.Google Scholar

Tietjen, G. E., Day, M., Norris, L., et al. 1998. Role of anticardiolipin antibodies in young persons with migraine and transient focal neurologic events. Neurology, 50, 1433–40.CrossRef Google Scholar PubMed

Toubi, E., Khamashta, M. A., Panarra, A., and Hughes, G. R. V. 1995. Association of antiphospholipid antibodies with central nervous system disease in systemic lupus erythematosus. Am J Med, 99, 397–401.Google Scholar

Tourbah, A., Peitte, J. C, Iba-Zizen, M., et al. 1997. The natural course of cerebral lesions in Sneddon syndrome. Arch Neurol, 54, 53–60.Google Scholar

Tuhrim, S., Rand, J. H., Wu, X., et al. 1999. Antiphosphatidylserine antibodies are independently associated with ischemic stroke. Neurology, 53, 1523–7.Google Scholar

Urbanus, R. T., Siegerink, B., Roest, M., et al. 2009. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: A case-control study. Lancet Neuro, 8, 998–1005.CrossRef Google Scholar PubMed

van Goor, M. R, Alblas, C. L., Leebeek, E W., Koudstaal, P. J., and Dippel, D. W. 2004. Do antiphospholipid antibodies increase the long-term risk of thrombotic complications in young patients with a recent TLA or ischemic stroke? Acta Neurol Scand, 109, 410–5.Google Scholar

Vega-Ostertag, M. E., Ferrara, D. E., Romay-Penabad, Z., et al. 2007. Role of p38 mitogen-activated protein kinase in antiphospholipid antibody-mediated thrombosis and endothelial cell activation. J Thromb Haemost, 5, 1828–1834.Google Scholar

Vermylen, J., Van Geet, C, and Arnout, J. 1998. Antibody-mediated thrombosis: Relation to the antiphospholipid syndrome. Lupus, 7, S63–6.Google Scholar

Vila, P., Hernandez, M. C., Lopez-Fernandez, M. E., and Baffle, J. 1994. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb Haemost, 72, 209–13.Google Scholar

Wahl, D. G., Guillemin, F., de Maistre, E., et al. 1998. Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. Lupus, 7, 15–22.Google Scholar

Wang, L., Chen, H., Zhang, Y., et al. 2015. Clinical characteristics of cerebral venous sinus thrombosis in patients with systemic lupus erythematosus: A single-centre experience in China. J Immunol Res, 2015, 1–7.Google Scholar

Zeiger, B., Sepp, N., Stockhammer, G., et al. 1993. Sneddon’s syndrome: A long term follow-up of 21 patients. Arch Dermatol, 129, 437–44.Google Scholar

Ziporen, L. and Shoenfeld, Y. 1998. Antiphospholipid syndrome: From patient’s bedside to experimental animal models and back to the patient’s bedside. Hematol Cell Ther, 40, 175–82.Google Scholar

Zuily, S., Regnault, V., Selton-Sulty, C., et al. 2011. Increased risk for heart valve disease associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: Meta-analysis of echocardiographic studies. Circulation, 124, 215–24.Google Scholar

References

Hardaway, R. M. Disseminated intravascular coagulation syndromes. Arch. Surg. Chic. Ill. 1960 83, 842–50 (1961).Google Scholar

Goodnight, S. H. et al. Defibrination after brain-tissue destruction: A serious complication of head injury. N. Engl. J. Med. 290, 1043–7 (1974).CrossRef Google Scholar PubMed

Gando, S., Nanzaki, S., Sasaki, S. & Kemmotsu, O. Significant correlations between tissue factor and thrombin markers in trauma and septic patients with disseminated intravascular coagulation. Thromb. Haemost. 79, 1111–15 (1998).Google Scholar

Gando, S. Disseminated intravascular coagulation in trauma patients. Semin. Thromb. Hemost. 27, 585–92 (2001).CrossRef Google Scholar PubMed

García-Avello, A. et al. Degree of hypercoagulability and hyperfibrinolysis is related to organ failure and prognosis after burn trauma. Thromb. Res. 89, 59–64 (1998).Google Scholar

Barbui, T. & Falanga, A. Disseminated intravascular coagulation in acute leukemia. Semin. Thromb. Hemost. 27, 593–604 (2001).Google Scholar

Arai, A. et al. Cardiac malignant pheochromocytoma with bone metastases. Intern. Med. Tokyo Jpn. 37, 940–4 (1998).Google Scholar

Letsky, E. A. Disseminated intravascular coagulation. Best Pract. Res. Clin. Obstet. Gynaecol. 15, 623–44 (2001).Google Scholar

Hossain, N. & Paidas, M. J. Disseminated intravascular coagulation. Semin. Perinatol. 37, 257–66 (2013).Google Scholar

Breakwell, L. M., Getty, C. J., & Austin, C. Disseminated intravascular coagulation in elective primary total hip replacement. J. Arthroplasty 14, 239–42 (1999).Google Scholar

Asherson, R. A. The catastrophic antiphospholipid syndrome, 1998. A review of the clinical features, possible pathogenesis and treatment. Lupus 7, S55–62 (1998).Google Scholar

Katsaros, D. & Grundfest-Broniatowski, S. Successful management of visceral Klippel–Trenaunay–Weber syndrome with the antifibrinolytic agent tranexamic acid (cyclocapron): A case report. Am. Surg. 64, 302–4 (1998).Google Scholar

Persoons, M. C., Stals, F. S., van dam Mieras, M. C., & Bruggeman, C. A. Multiple organ involvement during experimental cytomegalovirus infection is associated with disseminated vascular pathology. J. Pathol. 184, 103–9 (1998).Google Scholar

Lifshitz, M., Kapelushnik, J., Ben-Harosh, M., & Sofer, S. Disseminated intravascular coagulation after Cerastes vipera envenomation in a 3-year-old child: A case report. Toxicon Off. J. Int. Soc. Toxinology 38, 1593–8 (2000).Google Scholar

Bey, T. A. et al. Loxosceles arizonica bite associated with shock. Ann. Emerg. Med. 30, 701–3 (1997).Google Scholar

Jung, J. W. et al. A fatal case of intravascular coagulation after bee sting acupuncture. Allergy Asthma Immunol. Res. 4, 107–9 (2012).Google Scholar

Dhanapriya, J. et al. Acute kidney injury and disseminated intravascular coagulation due to mercuric chloride poisoning. Indian J. Nephrol. 26, 206 (2016).Google Scholar

Felcher, A. et al. Disseminated intravascular coagulation and status epilepticus. Neurology 51, 629–31 (1998).Google Scholar

Bick, R. L. Disseminated intravascular coagulation. Hematol. Oncol. Clin. North Am. 6, 1259–85 (1992).Google Scholar

Gando, S., Levi, M., & Toh, C.-H. Disseminated intravascular coagulation. Nat. Rev. Dis. Primer 2, 16037 (2016).Google Scholar

Dhainaut, J.-F., Macias, W. L., & Nelson, D. R. Would patients with more subtle signs of coagulopathy have benefited from treatment with activated protein C? Crit. Care Med. 33, 1670–1 (2005).Google Scholar

Taylor, F. B. et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb. Haemost. 86, 1327–30 (2001).Google Scholar

Favaloro, E. J. & Adcock, D. M. Standardization of the INR: How good is your laboratory’s INR and can it be improved? Semin. Thromb. Hemost. 34, 593–603 (2008).Google Scholar

Gando, S. et al. A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients: Comparing current criteria. Crit. Care Med. 34, 625–31 (2006).Google Scholar

Prechel, M. & Walenga, J. M. The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: An update. Semin. Thromb. Hemost. 34, 86–96 (2008).Google Scholar

Selleng, K., Selleng, S., & Greinacher, A. Heparin-induced thrombocytopenia in intensive care patients. Semin. Thromb. Hemost. 34, 425–38 (2008).Google Scholar

Schwartzman, R. J. & Hill, J. B. Neurologic complications of disseminated intravascular coagulation. Neurology 32, 791–7 (1982).Google Scholar

Shebuski, R. J. & Kilgore, K. S. Role of inflammatory mediators in thrombogenesis. J. Pharmacol. Exp. Ther. 300, 729–35 (2002).Google Scholar

Wada, H. et al. Hemostatic molecular markers before the onset of disseminated intravascular coagulation. Am. J. Hematol. 60, 273–8 (1999).Google Scholar

Favaloro, E. J. Laboratory testing in disseminated intravascular coagulation. Semin. Thromb. Hemost. 36, 458–67 (2010).Google Scholar

Levi, M. & van der Poll, T. The role of natural anticoagulants in the pathogenesis and management of systemic activation of coagulation and inflammation in critically ill patients. Semin. Thromb. Hemost. 34, 459–68 (2008).Google Scholar

de Jonge, E., van der Poll, T., Kesecioglu, J. & Levi, M. Anticoagulant factor concentrates in disseminated intravascular coagulation: Rationale for use and clinical experience. Semin. Thromb. Hemost. 27, 667–74 (2001).Google Scholar

Naidech, A. M. & Kumar, M. A., and the participants in the International Multidisciplinary Consensus Conference on Multimodality Monitoring. Monitoring of hematological and hemostatic parameters in neurocritical care patients. Neurocrit. Care 21, 168–76 (2014).Google Scholar

Johansson, P. I., Stensballe, J., Vindeløv, N., Perner, A., & Espersen, K. Hypocoagulability, as evaluated by thromboelastography, at admission to the ICU is associated with increased 30-day mortality. Blood Coagul. Fibrinolysis 21, 168–74 (2010).Google Scholar

Park, M. S. et al. Thromboelastography as a better indicator of hypercoagulable state after injury than prothrombin time or activated partial thromboplastin time. J. Trauma 67, 266–76 (2009).Google Scholar

Bakhtiari, K., Meijers, J. C. M., de Jonge, E., & Levi, M. Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation. Crit. Care Med. 32, 2416–21 (2004).Google Scholar

Gando, S. et al. Evaluation of new Japanese diagnostic criteria for disseminated intravascular coagulation in critically ill patients. Clin. Appl. Thromb. Off. J. Int. Acad. Clin. Appl. Thromb. 11, 71–6 (2005).Google Scholar

Sivula, M., Tallgren, M., & Pettilä, V. Modified score for disseminated intravascular coagulation in the critically ill. Intensive Care Med. 31, 1209–14 (2005).Google Scholar

Cauchie, P. et al. Diagnosis and prognosis of overt disseminated intravascular coagulation in a general hospital – meaning of the ISTH score system, fibrin monomers, and lipoprotein-C-reactive protein complex formation. Am. J. Hematol. 81, 414–19 (2006).Google Scholar

Umemura, Y. et al. Design and evaluation of new unified criteria for disseminated intravascular coagulation based on the Japanese Association for Acute Medicine criteria. Clin. Appl. Thromb. Off. J. Int. Acad. Clin. Appl. Thromb. 22, 153–60 (2016).Google Scholar

Angstwurm, M. W. A., Dempfle, C.-E., & Spannagl, M. New disseminated intravascular coagulation score: A useful tool to predict mortality in comparison with Acute Physiology and Chronic Health Evaluation II and Logistic Organ Dysfunction scores. Crit. Care Med. 34, 314–20; quiz 328 (2006).Google Scholar

Toh, C. H. & Downey, C. Performance and prognostic importance of a new clinical and laboratory scoring system for identifying non-overt disseminated intravascular coagulation. Blood Coagul. Fibrinolysis Int. J. Haemost. Thromb. 16, 69–74 (2005).Google Scholar

Cartin-Ceba, R. et al. Epidemiology of critical care syndromes, organ failures, and life-support interventions in a suburban US community. Chest 140, 1447–55 (2011).Google Scholar

Gando, S. et al. Natural history of disseminated intravascular coagulation diagnosed based on the newly established diagnostic criteria for critically ill patients: Results of a multicenter, prospective survey. Crit. Care Med. 36, 145–50 (2008).Google Scholar

Wheeler, A. P. & Bernard, G. R. Treating patients with severe sepsis. N. Engl. J. Med. 340, 207–14 (1999).Google Scholar

Levi, M., de Jonge, E., & van der Poll, T. Sepsis and disseminated intravascular coagulation. J. Thromb. Thrombolysis 16, 43–7 (2003).Google Scholar

Lavrentieva, A. et al. Early coagulation disorders after severe burn injury: Impact on mortality. Intensive Care Med. 34, 700–6 (2008).Google Scholar

Barret, J. P. & Gomez, P. A. Disseminated intravascular coagulation: A rare entity in burn injury. Burns J. Int. Soc. Burn Inj. 31, 354–7 (2005).Google Scholar

Singh, B. et al. Trends in the incidence and outcomes of disseminated intravascular coagulation in critically ill patients (2004–2010): A population-based study. Chest 143, 1235–42 (2013).Google Scholar

Ranieri, V. M. et al. Drotrecogin alfa (activated) in adults with septic shock. N. Engl. J. Med. 366, 2055–64 (2012).Google Scholar

Murata, A., Okamoto, K., Mayumi, T., Muramatsu, K. & Matsuda, S. The recent time trend of outcomes of disseminated intravascular coagulation in Japan: An observational study based on a national administrative database. J. Thromb. Thrombolysis 38, 364–71 (2014).Google Scholar

Hoffman, M. & Monroe, D. M. A cell-based model of hemostasis. Thromb. Haemost. 85, 958–65 (2001).Google Scholar

Franco, R. F. et al. The in vivo kinetics of tissue factor messenger RNA expression during human endotoxemia: Relationship with activation of coagulation. Blood 96, 554–9 (2000).Google Scholar

Levi, M. & van der Poll, T. Inflammation and coagulation. Crit. Care Med. 38, S26–34 (2010).Google Scholar

Rauch, U. et al. Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood 96, 170–5 (2000).Google Scholar

Zimmerman, G. A., McIntyre, T. M., Prescott, S. M., & Stafforini, D. M. The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit. Care Med. 30, S294–301 (2002).Google Scholar

Bockmeyer, C. L. et al. Inflammation-associated ADAMTS 13 deficiency promotes formation of ultra-large von Willebrand factor. Haematologica 93, 137–40 (2008).Google Scholar

Osterud, B. & Bjørklid, E. The production and availability of tissue thromboplastin in cellular populations of whole blood exposed to various concentrations of endotoxin. An assay for detection of endotoxin. Scand. J. Haematol. 29, 175–84 (1982).Google Scholar

Engelmann, B. & Massberg, S. Thrombosis as an intravascular effector of innate immunity. Nat. Rev. Immunol. 13, 34–45 (2013).Google Scholar

Müller, I. et al. Intravascular tissue factor initiates coagulation via circulating microvesicles and platelets. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 17, 476–8 (2003).Google Scholar

Fuchs, T. A. et al. Extracellular DNA traps promote thrombosis. Proc. Natl. Acad. Sci. USA 107, 15880–5 (2010).Google Scholar

von Brühl, M.-L. et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J. Exp. Med. 209, 819–35 (2012).Google Scholar

Massberg, S. et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat. Med. 16, 887–96 (2010).Google Scholar

Franchini, M. Pathophysiology, diagnosis and treatment of disseminated intravascular coagulation: An update. Clin. Lab. 51, 633–9 (2005).Google Scholar

Lineaweaver, W., Franzini, D., Dragonetti, D., McCarley, D., & Rumley, T. Haemophilus influenzae meningitis and Waterhouse–Friderichsen syndrome in an adult. South. Med. J. 79, 1034–6 (1986).Google Scholar

Ohashi, R. et al. Acute renal failure as the presenting sign of disseminated intravascular coagulation in a patient with metastatic prostate cancer. Int. J. Nephrol. Renov. Dis. 6, 47–51 (2013).Google Scholar

Bick, R. L. Disseminated intravascular coagulation: Pathophysiological mechanisms and manifestations. Semin. Thromb. Hemost. 24, 3–18 (1998).Google Scholar

Collins, R. C., Al-Mondhiry, H., Chernik, N. L., & Posner, J. B. Neurologic manifestations of intravascular coagulation in patients with cancer. A clinicopathologic analysis of 12 cases. Neurology 25, 795–806 (1975).Google Scholar

Graus, F., Rogers, L. R., & Posner, J. B. Cerebrovascular complications in patients with cancer. Medicine (Baltimore) 64, 16–35 (1985).Google Scholar

Wijdicks, E. F. & Scott, J. P. Stroke in the medical intensive-care unit. Mayo Clin. Proc. 73, 642–6 (1998).Google Scholar

Navi, B. B. et al. Intracerebral and subarachnoid hemorrhage in patients with cancer. Neurology 74, 494–501 (2010).Google Scholar

Goodnight, S. H. Bleeding and intravascular clotting in malignancy: A review. Ann. N. Y. Acad. Sci. 230, 271–88 (1974).Google Scholar

Pisoni, R., Ruggenenti, P. & Remuzzi, G. Drug-induced thrombotic microangiopathy: Incidence, prevention and management. Drug Saf. 24, 491–501 (2001).Google Scholar

Nguyen, T. C. & Carcillo, J. A. Bench-to-bedside review: Thrombocytopenia-associated multiple organ failure – a newly appreciated syndrome in the critically ill. Crit. Care Lond. Engl. 10, 235 (2006).Google Scholar

Johnson, R. T. & Richardson, E. P. The neurological manifestations of systemic lupus erythematosus. Medicine (Baltimore) 47, 337–69 (1968).Google Scholar

Musio, F., Bohen, E. M., Yuan, C. M., & Welch, P. G. Review of thrombotic thrombocytopenic purpura in the setting of systemic lupus erythematosus. Semin. Arthritis Rheum. 28, 1–19 (1998).Google Scholar

Yasuda, S., Bohgaki, M., Atsumi, T. & Koike, T. Pathogenesis of antiphospholipid antibodies: Impairment of fibrinolysis and monocyte activation via the p38 mitogen-activated protein kinase pathway. Immunobiology 210, 775–80 (2005).Google Scholar

Galli, M. Treatment of the antiphospholipid syndrome. Auto- Immun. Highlights 5, 1–7 (2014).Google Scholar

Cervera, R. & Espinosa, G. Update on the catastrophic antiphospholipid syndrome and the ‘CAPS Registry’. Semin. Thromb. Hemost. 38, 333–8 (2012).Google Scholar PubMed

van Runnard Heimel, P. J. et al. A randomised placebo-controlled trial of prolonged prednisolone administration to patients with HELLP syndrome remote from term. Eur. J. Obstet. Gynecol. Reprod. Biol. 128, 187–193 (2006).Google Scholar

Pijnenborg, R., Vercruysse, L., Hanssens, M. & Brosens, I. Endovascular trophoblast and preeclampsia: A reassessment. Pregnancy Hypertens. 1, 66–71 (2011).Google Scholar

Warkentin, T. Heparin-induced thrombocytopenia in critically ill patients. Semin. Thromb. Hemost. 41, 049–60 (2015).Google Scholar

Warkentin, T. E., Sheppard, J.-A. I., Moore, J. C., Cook, R. J., & Kelton, J. G. Studies of the immune response in heparin-induced thrombocytopenia. Blood 113, 4963–9 (2009).Google Scholar

Hanly, E. J., Cohn, E. J., Johnson, J. L., & Peyton, B. D. DIC: Treatment frontiers. Curr. Surg. 59, 257–64 (2002).Google Scholar

Levi, M., Toh, C. H., Thachil, J., & Watson, H. G. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br. J. Haematol. 145, 24–33 (2009).Google Scholar

Wada, H. et al. Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thromb. Res. 125, 6–11 (2010).Google Scholar

Kawasugi, K. et al. Prospective evaluation of hemostatic abnormalities in overt DIC due to various underlying diseases. Thromb. Res. 128, 186–90 (2011).Google Scholar

Alving, B. M., Spivak, J. L., DeLoughery, T. G. Consultative hematology: Hemostasis and transfusion issues in surgery and critical care medicine. Hematology Am. Soc. Hematol. Educ. Program 320–41, 1998.Google Scholar

Slichter, S. J. Evidence-based platelet transfusion guidelines. Hematol. Am. Soc. Hematol. Educ. Program 172–78 (2007). doi:10.1182/asheducation-2007.1.172Google Scholar

Wada, H. et al. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J. Thromb. Haemost. (2013). doi:10.1111/jth.12155.Google Scholar

Sakuragawa, N., Hasegawa, H., Maki, M., Nakagawa, M. & Nakashima, M. Clinical evaluation of low-molecular-weight heparin (FR-860) on disseminated intravascular coagulation (DIC): A multicenter co-operative double-blind trial in comparison with heparin. Thromb. Res. 72, 475–500 (1993).Google Scholar

Simpson, E. et al. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst. Rev. CD005011 (2012). doi:10.1002/14651858.CD005011.pub4.Google Scholar

Liu, X.-L. et al. Low-dose heparin as treatment for early disseminated intravascular coagulation during sepsis: A prospective clinical study. Exp. Ther. Med. 7, 604–8 (2014).Google Scholar

Corrigan, J. J. & Jordan, C. M. Heparin therapy in septicemia with disseminated intravascular coagulation: Effect on mortality and on correction of hemostatic defects. N. Engl. J. Med. 283, 778–82 (1970).Google Scholar

Gando, S., Sawamura, A., & Hayakawa, M. Trauma, shock, and disseminated intravascular coagulation: Lessons from the classical literature. Ann. Surg. 254, 10–19 (2011).Google Scholar

Vincent, J.-L. et al. A randomized, double-blind, placebo-controlled, phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit. Care Med. 41, 2069–79 (2013).Google Scholar

Jaimes, F. et al. Unfractioned heparin for treatment of sepsis: A randomized clinical trial (the HETRASE study). Crit. Care Med. 37, 1185–96 (2009).Google Scholar

Okajima, K. & Uchiba, M. The anti-inflammatory properties of antithrombin III: new therapeutic implications. Semin. Thromb. Hemost. 24, 27–32 (1998).Google Scholar

Fourrier, F., Jourdain, M. & Tournoys, A. Clinical trial results with antithrombin III in sepsis. Crit. Care Med. 28, S38–43 (2000).Google Scholar

Saito, H. et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: Results of a phase III, randomized, double-blind clinical trial. J. Thromb. Haemost. 5, 31–41 (2007).Google Scholar

Yamakawa, K. et al. Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: A historical control study. Crit. Care Lond. Engl. 15, R123 (2011).Google Scholar

Abraham, E. et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N. Engl. J. Med. 353, 1332–41 (2005).Google Scholar

Abraham, E. et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: A multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit. Care Med. 29, 2081–9 (2001).Google Scholar

CRASH-2 trial collaborators et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): A randomised, placebo-controlled trial. Lancet Lond. Engl. 376, 23–32 (2010).Google Scholar

CRASH-2 Collaborators, Intracranial Bleeding Study. Effect of tranexamic acid in traumatic brain injury: A nested randomised, placebo controlled trial (CRASH-2 Intracranial Bleeding Study). BMJ 343, d3795 (2011).Google Scholar

References

Ansell, JE. 2016. Universal, class-specific and drug-specific reversal agents for the new oral anticoagulants. J Thromb Thrombolyisis 41: 248–52.Google Scholar

Baharoglu, MI, Cordonnier, C, Al-Shai Salman, R, et al. 2016. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral hemorrhage associated with antiplatelet therapy (PATCH): A randomized, open-label, phase 3 trial. Lancet 387: 2605–13.Google Scholar

Casari, C, Bergmeier, W. 2016. Acquired platelet disorders. Thromb Res 141: S73–5.Google Scholar

Cervera, A, Amaro, S, Chamorro, A. 2012. Oral anticoagulant-associated intracerebral hemorrhage. J Neurol 259: 212–24.Google Scholar

Chen, C-Y, Tai, C-H, Tsay, W, et al. 2009. Prediction of fatal intracranial hemorrhage in patients with acute myeloid leukemia. Annals Oncol 20: 1100–4.Google Scholar

Chen, C-Y, Tai, C-H, Cheng, A et al. 2012. Intracranial hemorrhage in adult patients with hematologic malignancies. BMC Medicine 10: 97. doi: 10.1186/1741–7015–10–97.Google Scholar

Chern, JJ, Tsung, AJ, Humphries, W, et al. 2011. Clinical outcome of leukemia patients with intracranial hemorrhage. Clinical article. J Neurosurg 115: 268–72.Google Scholar

Coppola, A, Tagliaferri, A, Franchini, M. 2016. Controversies in inherited bleeding disorders. Semin Thromb Hemost 42: 459–62.Google Scholar

Diringer, MN, Skolnick, BE, Mayer, SA, et al. 2010. Thromboembolic events with recombinant activated factor VII in spontaneous intracerebral hemorrhage: results from the factor seven for acute hemorrhagic stroke (FAST) trial. Stroke 41: 48–53.Google Scholar

Emiru, T, Bershad, EM, Zantek, ND, et al. 2012. Intracerebral hemorrhage: A review of coagulation function. Clin Appl Thromb Hemost. doi: 0.1177/1076029612454938.Google Scholar

Estcourt, LJ, Stanworth, SJ, Collett, D, et al. 2014. Intracranial hemorrhage in thrombocytopenic hematology patients – a nested case-control study: The InCiTe study protocol. BMJ Open 4: e004199.Google Scholar

Flaherty, ML, Tao, H, Haverbusch, M, et al. 2008. Warfarin use leads to larger intracerebral hematomas. Neurology 71: 1084–9.Google Scholar

Foerch, C, Sitzer, M, Steinmetz, H, et al. 2006 Pretreatment with antiplatelet agents is not independently associated with unfavorable outcome in intracerebral hemorrhage. Stroke 37: 2165–7.Google Scholar

Goldszmidt, AJ, Caplan, LR. 2010. Stroke Essentials, 2nd edn. Sudbury, MA: Jones & Bartlett Publishers.Google Scholar

Gonzalez-Duarte, A, Garcia-Ramos, GS, Valdes-Ferrer, SI, et al. 2008 Clinical description of intracranial hemorrhage associated with bleeding disorders. J Stroke Cerebrovasc Dis 17: 204–7.Google Scholar

Granger, CB, Alexander, JH, McMurray, JJ, et al. 2011. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365: 981–92.Google Scholar

Gresele, P, Bury, L, Falcinelli, E. 2016. Inherited platelet function disorders: Algorithms for phenotypic and genetic investigation. Semin Thromb Hemost 42: 292–305.Google Scholar

Lauer, A, Pfeilschifter, W, Schaffer, CB, et al. 2013. Intracerebral hemorrhage associated with antithrombotic treatment: Translational insights from experimental studies. Lancet Neurol 12: 394–405.Google Scholar

Maas, MB, Forsenbery, NF, Kosteva, AR, et al. 2013. Coagulopathy disproportionately predisposes to lobar intracerebral hemorrhage. Neurocrit Care 18: 166–9.Google Scholar

Naidech, AM, Bernstein, RA, Levasseur, K, et al. 2009a. Platelet activity and outcome after intracerebral hemorrhage. Ann Neurol 65: 352–6.Google Scholar

Naidech, AM, Jovanovic, B, Liebling, S, et al. 2009b. Reduced platelet activity is associated with early clot growth and worse 3-month outcome after intracerebral hemorrhage. Stroke 40: 2398–401.Google Scholar

National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. 1995. N Engl J Med 333: 1581–7.Google Scholar

O’Carroll, CB, Aguilar, MI. 2015. Management of post-thrombolysis hemorrhagic and orolingual angioedema complications. Neurohospitalist 5: 133–41.Google Scholar

Patel, MR, Mahaffey, KW, Garg, J, et al. 2011. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365: 883–91.Google Scholar

Pezzini, A, Grassi, M, Paciaroni, M, et al. 2014. Antithrombotic medications and the etiology of intracerebral hemorrhage: MUCH-Italy. Neurology 82: 529–35.Google Scholar

Pollack, CV, Reilly, PA, Eikelborn, J, et al. 2015. Idarucizumab for dabigatran reversal. N Engl J Med 373: 511–20.Google Scholar

Purrucker, JC, Haas, K, Rizos, T, et al. 2016. Early clinical and radiological course, management, and outcome of intracerebral hemorrhage related to new oral anticoagulants. JAMA Neurol 73: 169–77.Google Scholar

Quiñones-Hinojosa, A, Gulati, M, Singh, V, et al. 2003. Spontaneous intracerebral hemorrhage due to coagulation disorders. Neurosurg Focus 15: E3.Google Scholar

Saloheimo, P, Ahonen, M, Juvela, S, et al. 2006. Regular aspirin-use preceding the onset of primary intracerebral hemorrhage is an independent predictor for death. Stroke 37: 129–33.Google Scholar

Sandrock-Lang, K, Wentzell, R, Santoso, S, et al. 2015. Inherited platelet disorders. Hamostaseologie 35: 2.Google Scholar

Sterrenberg, D, Nand, S. 2016. Congenital coagulation disorders. In Anticoagulation and Hemostasis in Neurosurgery, 1st edn, ed. Loftus, C. M.. Switzerland: Springer International Publishing, pp. 93–114.Google Scholar

Wijman, CA. 2009. Is platelet activity important in acute intracerebral hemorrhage? Neurocrit Care 11: 305–6.Google Scholar

Wilson, D, Charidimou, A, Shakeshaft, C, et al. 2016. Volume and functional outcome of intracerebral hemorrhage according to oral anticoagulant type. Neurology 86: 360–6.Google Scholar

Yasaka, M, Sakata, T, Naritomi, H, et al. 2005. Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation. Thromb Res 115: 455–59.Google Scholar

Yates, S, Sarode, R. 2015. Reversal of anticoagulant effects in patients with intracerebral hemorrhage. Curr Neurol Neurosci Rep 15: 1–10.Google Scholar

References

Mannucci, PM. Laboratory detection of inherited thrombophilia: A historical perspective. Semin Thromb Hemost 2005; 32: 5–10.Google Scholar

Ma, K, Wells, P, Guzman, C, et al. A multicenter prospective study of risk factors and treatment of unusual site thrombosis. Thromb Res 2016; 144: 100–5.Google Scholar

Guria, K, Guria, GT. Spatial aspects of blood coagulation: Two decades of the self-sustained traveling wave of thrombin. Thromb Res 2015; 135: 423–33.Google Scholar

Boilard, E, Duchez, A-C, Brisson, A. The diversity of platelet microparticles. Curr Opin Hematol 2015; 22: 437–44.Google Scholar

van Roos, M-J, Pretorius, E. Metabolic syndrome, platelet activation and development of transient ischemic attack or thromboembolic stroke. Thromb Res 2015; 135: 434–42.Google Scholar

Yau, JW, Teoh, H, Verma, S. Endothelial control of thrombosis. BMC Cardiovasc Disord 2015; 15: 130.Google Scholar

van Hinsbergh, VWM. Endothelium: Role in regulation of coagulation and inflammation. Semin Immunopathol 2012; 34: 93–106.Google Scholar

Tjarnlund-Wolf, A, Brogren, H, Lo, EH, Wang, X. Plasminogen activator inhibitor-1 and thrombotic cerebrovascular diseases. Stroke 2012; 43: 2833–9.CrossRef Google Scholar PubMed

Aleman, MM, Walton, BL, Byrnes, JR, Wolberg, AS. Fibrinogen and red blood cells in venous thrombosis. Thromb Res 2014; 133: S38–40.Google Scholar

Davies, PF. Hemodynamic shear stress and the endothelium in cardiovascular pathophysiology. Nat Clin Pract Cardiovasc Med 2009; 6: 16–26.Google Scholar

Wardlaw, JW, Smith, C, Dichgans, M. Mechanisms underlying sporadic cerebral small vessel disease: Insights from neuroimaging. Lancet Neurol 2013; 12: 483–97.Google Scholar

Fisher, CM. Cerebral military aneurysms in hypertension. Am J Pathol 1972; 66: 313–30.Google Scholar

Fisher, MJ. Brain regulation of thrombosis and hemostasis: From theory to practice. Stroke 2013; 44: 3275–85.Google Scholar

Szymanska, M, Alhenc-Gelas, M, Undas, A. Recurrent ischemic cerebrovascular events in a patient with type I antithrombin deficiency caused by 9788 G>A splice site mutation: A case report. Blood Coag Fibrinol 2013; 24: 213–15.Google Scholar

Kovac, M, Mitic, G, Mikovic, Z, et al. Pregnancy related stroke in the setting of homozygous type-II HBS antithrombin deficiency. Thromb Res 2016; 139: 111–13.Google Scholar

Kuhle, S, Lane, DA, Jochmanns, K, et al. Homozygous antithrombin deficiency type II (99 Leu to Phe mutation) and childhood thromboembolism. Thromb Haemost 2001; 86: 1007–11.Google Scholar

Knuiman, MW, Folsom, AR, Chambles, LE, Liao, D, Wu, KK. Association of hemostatic variables with MRI-detected cerebral abnormalities: The atherosclerosis risk in communities study. Neuroepidemiology 2001; 20: 96–104.Google Scholar

de Lau, LML, Leebeek, FWG, de Maat, MPM, Koudstaal, PJ, Dippel, DWJ. A review of hereditary and acquired coagulation disorders in the aetiology of ischaemic stroke. Int J Stroke 2010; 5: 385–94.Google Scholar

Stam, J. Thrombosis of the cerebral veins and sinuses. N Engl J Med 2005; 352: 1791–98.Google Scholar

Kujovich, JC. Factor V Leiden thrombophilia. Genet Med 2011; 13: 1–16.Google Scholar

Mumford, AD, McVey, JH, Morse, CV, et al. Factor V I359T: A novel mutation associated with thrombosis and resistance to activated protein C. Br J Haematol 2003; 123: 496–501.Google Scholar

Chan, WP, Lee, CK, Kwong, YL, Lam, CK, Liang, R. A novel mutation of Arg306 of factor V gene in Hong Kong Chinese. Blood 1998; 91: 1135–9.Google Scholar

Lalouschek, W, Schillinger, M, Hsieh, K, et al. Matched case–control study on factor V Leiden and the prothrombin G20210A mutation in patients with ischemic stroke/transient ischemic attack up to the age of 60 years. Stroke 2005; 36: 1405–1409.Google Scholar

Tofler, GH, Massaro, J, O’Donnell, CJ, et al. Plasminogen activator inhibitor and risk for cardiovascular disease: The Framingham Heart Study. Thromb Res 2016; 140: 30–5.Google Scholar

Nave, AH, Lange, KS, Leonards, CO, et al. Lipoprotein (a) as a risk factor for ischemic stroke: A meta-analysis. Atherosclerosis 2015; 242: 496–503.CrossRef Google Scholar PubMed

Jiang, B, Ryan, KA, Hamedani, A, et al. Prothrombin G20210A mutation is associated with young-onset stroke. Stroke 2014; 45: 961–7.Google Scholar

Lonn, E, Yusuf, S, Arnold, MJO, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354: 1567–77.Google Scholar

Nah, H-W, Kim, JS. Premature intracranial arterial calcification in a patient with hyperhomocysteinemia. Neurology 2010; 75: 2252.Google Scholar

Saposnik, G, Ray, JG, Sheridan, P, et al. Homocysteine-lowering therapy and stroke risk, severity, and disability: Additional findings from the HOPE 2 trial. Stroke 2009; 40: 1365–72.Google Scholar

Hankey, GJ, Eikelboom, JW, Yi, Q, et al. Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: A post-hoc subanalysis of VITATOPS, a randomised, placebo-controlled trial. Lancet Neurol 2012; 11: 512–20.Google Scholar

George, JN, Nester, CM. Syndromes of thrombotic microangiopathy. New Eng J Med 2014; 371: 654–66.Google Scholar

Shen, YM. Clinical evaluation of thrombotic microangiopathy: Identification of patients with suspected atypical hemolytic uremic syndrome. Thromb J 2016; 14: 19.Google Scholar

Kavanagh, D, McGlasson, S, Jury, A, et al. Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature. Blood 2016; 128: 2824–33.Google Scholar

Al-Nouri, ZL, Reese, JA, Terrell, DR, et al. Drug-induced thrombotic microangiopathy: A systematic review of published reports. Blood 2015; 125: 616–18.Google Scholar

Luzzatto, L. Recent advances in the pathogenesis and treatment of paroxysmal nocturnal hemoglobinuria. F1000Research 2016, doi: 10.12688/f1000research.7288.1.Google Scholar

de Latour, RP, Mary, JY, Salanoubat, C, et al. Paroxysmal nocturnal hemoglobinuria: Natural history of disease subcategories. Blood 2008; 112: 3099–106.Google Scholar

Meppiel, E, Crassard, J, de Latour, RP, et al. Cerebral venous thrombosis in paroxysmal nocturnal hemoglobinuria. Medicine 2015; 94: 1–8.Google Scholar

Helley, D, de Latour, RP, Porcher, R, et al. Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Haematologica 2010; 95: 574–81.Google Scholar

DeZern, AE, Brodsky, RA. Paroxysmal nocturnal hemoglobinuria. Hematolol Oncol Clin North Am 2015; 29: 479–94.Google Scholar

Artoni, A, Bucciarelli, P, Martinelli I. Cerebral thrombosis and myeloproliferative neoplasms. Curr Neurol Neurosci Rep 2014; 14: 496.Google Scholar

Crespo, AM, Abraira, L, Guanyabens, N, et al. Recurrent stroke with rapid development of intracranial stenosis in polycythemia vera. J Stroke Cerebrovasc Dis 2016; 25: e41–3.Google Scholar

Tanashyan, MM, Kuznetsova, PI, Shabalina, AA, et al. Clinical characteristics of cerebrovascular pathology with patients suffering from Ph-negative myeloproliferative disease. Cerebrovascular Diseases Extra 2016; 6: 66–70.Google Scholar

Khandelwal, S, Arepally, GM. Immune pathogenesis of heparin-induced thrombocytopenia. Thromb Haemost 2016; 116: 792–8.Google Scholar

Itaabashi, R, Yazawa, Y, Kawata, K, et al. Paradoxical brain emboli related to heparin-induced thrombocytopenia after catheter ablation. J Stroke Cerebrovasc Dis 2015; 24: e219–21.Google Scholar

Cundiff, DK. Anticoagulants for cerebral venous thrombosis. Stroke 2014; 45: 298–304.Google Scholar

Warkentin, TE. Clinical picture of heparin-induced thrombocytopenia (HIT) and its differentiation from non-HIT thrombocytopenia. Thromb Haemost 2016; 116: 813–22.Google Scholar

Centers for Disease Control and Prevention. Reproductive health: Pregnancy mortality surveillance system. http://www.cdc.gov/reproductivehealth/maternalinfanthealth/PMSS.html. Published 2014. Accessed July 18, 2015.Google Scholar

Simcox, LE, Ormesher, L, Tower, C, Greer, IA. Thrombophilia and pregnancy complications. Int J Mol Sci 2015; 16: 28418–28.Google Scholar

Kamel, H, Navi, BB, Sriram, N, et al. Risk of a thrombotic event after the 6-week postpartum period. N Engl J Med 2014; 370: 1307–15.Google Scholar

Lockwood, C, Wendel, G. Practice bulletin no. 124: Inherited thrombophilias in pregnancy. Obstet Gynecol 2011; 118: 730–40.Google Scholar

Centers for Disease Control and Prevention. WISQARS Database. Twenty Leading Causes of Death by Age Group, United States 2010. Available online at: http://www.cdc.gov/Injury/wisqars/.Google Scholar

Roach, ES, Golomb, MR, Adams, R, et al. Management of stroke in infants and children: A scientific statement from a special writing group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young. Stroke 2008; 39: 2644–91.Google Scholar

Amlie-Ledfond, C, Sebire, G, Fullerton, HJ. Recent developments in childhood arterial ischemic stroke. Lancet Neurol 2008; 7: 425.Google Scholar

Mackay, MT, Wiznitzer, M, Benedict, SL, et al. Arterial ischemic stroke risk factors: The International Pediatric Stroke Study. Ann Neurol 2011; 69: 130–40.Google Scholar

Schmidt, B, Andrew, M. Neonatal thrombosis: Report of a prospective Canadian and international registry. Pediatrics 1995; 96: 939–43.Google Scholar

Andrew, M, David, M, Adams, M, et al. Venous thromboembolic complications (VTE) in children: First analyses of the Canadian Registry of VTE. Blood 1994; 83: 1251–7.Google Scholar

Shroff, M, deVeber, G. Sinovenous thrombosis in children. Neuroimaging Clin N Am 2003; 13: 115–38.Google Scholar

deVeber, G, Andrew, M, Adams, C, et al. Cerebral sinovenous thrombosis in children. N Engl J Med 2001; 345: 417–23.Google Scholar

Mallick, AA, Ganesan, V, Kirkham, FJ, et al. Childhood arterial ischaemic stroke incidence, presenting features, and risk factors: A prospective population-based study. Lancet Neurol 2014; 13: 35–43.Google Scholar

Kenet, Gili, Aronis, S, Berkun, Y, et al. Impact of thrombophilia on risk of arterial ischemic stroke or cerebral sinovenous thrombosis in neonates and children a systematic review and meta-analysis of observational studies. Circulation 2010; 121: 1838–47.Google Scholar

Yang, JYK, Chan, AKC. Pediatric thrombophilia. Pediatr Clin N Am 2013; 60: 1443–62.Google Scholar

Monagle, P, Adams, M, Mahoney, M, et al. Outcome of pediatric thromboembolic disease: A report from the Canadian Childhood Thrombophilia Registry. Pediatr Res 2000; 47: 763–6.Google Scholar

Chalmers, EA. Epidemiology of venous thromboembolism in neonates and children. Thromb Res 2006; 118: 3–12.Google Scholar

References

Allford, S. L., Hunt, B. J., Rose, P., and Machin, S. J. 2003. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol, 120, 556–73.Google Scholar

Alungal, J., Abdulla, M. C., Koya, J. M., and Jenner, P. F. 2014. Multiple hemorrhagic infarcts in thrombotic thrombocytopenic purpura. Neurol India, 62, 582–3.Google Scholar

Amorosi, E. L. and Ultmann, J. E. 1966. Thrombotic thrombocytopenic purpura: Report of 16 cases and review of the literature. Medicine (Baltimore), 45, 139–59.Google Scholar

Asada, Y., Sumiyoshi, A., Hayashi, T., Suzumiya, J., and Kaketani, K. 1985. Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen. Thromb Res, 8, 469–79.Google Scholar

Bakshi, R., Shaikh, Z. A., Bates, V. E., and Kinkel, P. R. 1999. Thrombotic thrombocytopenic purpura: Brain CT and MRI findings in 12 patients. Neurology, 52, 1285–8.Google Scholar

Balduini, C.L., Gugliotta, L., Luppi, M., et al. 2010. High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: A randomized study. Ann Hematol, 89, 591–6.Google Scholar

Bellante, F., Redondo Saez, P., Springael, C., and Dethy, S. 2014. Stroke in thrombotic thrombocytopenic purpura induced by thyrotoxicosis: A case report. J Stroke Cerebrovasc Dis, 23, 1744–6.Google Scholar

Ben-Yehuda, D., Rose, M., Michaeli, T., and Eldor, A. 1998. Permanent neurological complications in patients with thrombotic thrombocytopenic purpura. Am J Hematol, 29, 74–8.Google Scholar

Bettoni, G., Palla, R., Valsecchi, C., et al. 2012. ADAMTS-13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura. J Thromb Haemost, 10, 1556–65.Google Scholar

Blombery, P. and Scully, M. 2014. Management of thrombotic thrombocytopenic purpura: Current perspectives. J Blood Med, 5, 15–23.Google Scholar

Cataland, S. R. and Wu, H. M. 2005. Immunotherapy for thrombotic thrombocytopenic purpura. Curr Opin Hematol, 12, 359–63.Google Scholar

Cataland, S. R. and Wu, H. M. 2015. Acquired thrombotic thrombocytopenic purpura: New therapeutic options and their optimal use. J Thromb Haemost, 13 (Suppl 1), S223–9.Google Scholar

Crawley, J. T. B. and Scully, M. A. 2013 Thrombotic thrombocytopenic purpura: Basic pathophysiology and therapeutic strategies. Hematol Am Soc Hematol Educ Program 2013, 292–9.Google Scholar

D’Aprile, P., Farchi, G., Pagliarulo, R., and Carella, A. 1994. Thrombotic thrombocytopenic purpura: MR demonstration of reversible brain abnormalities. Am J Neuroradiol, 15, 19–20.Google Scholar

Ellchuk, T. N., Shah, L. M., Hewlett, R. H., and Osborn, A. G. 2011. Suspicious neuroimaging pattern of thrombotic microangiopathy. Am J Neuroradiol, 32, 734–8.Google Scholar

Fagniez, O., Tertian, G., Dreyfus, M., et al. 2011. Hematological disorders related cerebral infarctions are mostly multifocal. J Neurol Sci, 304, 87–92.Google Scholar

Froissart, A., Buffet, M., Veyradier, A., et al. 2012. Efficacy and safety of firstline rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med, 40, 104–11.Google Scholar

Fujikawa, K., Suzuki, H., McMullen, B., and Chung, D. 2001. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood, 98, 1662–6.Google Scholar

Fujimura, Y., Matsumoto, M., Isonishi, A., et al. 2011. Natural history of Upshaw–Schulman syndrome based on ADAMTS13 gene analysis in Japan. J Thromb Haemost, 9 (Suppl 1), 283–301.Google Scholar

Furlan, M. and Lämmle, B. 2001. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: The role of von Willebrand factor-cleaving protease. Best Pract Res Clin Haematol, 14, 437–54.Google Scholar

Furlan, M., Robles, R., Galbusera, M., et al. 1998. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. N Engl J Med, 339, 1578–84.Google Scholar

George, J. N. 2010. How I treat patients with thrombocytopenic thrombotic purpura. Blood, 116, 4060–9Google Scholar

Griffin, D., Al-Nouri, Z. L., Muthurajah, D., et al. 2013 First symptoms in patients with thrombotic thrombocytopenic purpura (TTP): What are they and when do they occur? Transfusion, 53, 235–7.Google Scholar

Gurkan, E., Baslamisli, F., Guvenc, B., et al. 2005. Thrombotic thrombocytopenic purpura in southern Turkey: A single-center experience of 29 cases. Clin Lab Haematol, 27, 121–5.Google Scholar

Han, B., Page, E. E., Stewart, L. M., et al. 2015. Depression and cognitive impairment following recovery from thrombotic thrombocytopenic purpura. Am J Hematol, 90, 709–14.Google Scholar

Hoirisch-Clapauch, S. and Nardi, A. E. 2014. A role for tissue plasminogen activator in thrombotic thrombocytopenic purpura. Med Hypotheses, 83, 747–50.Google Scholar

Horton, T. M., Stone, J. D., Yee, D., et al. 2003. Case series of thrombotic thrombocytopenic purpura in children and adolescents. J Pediatr Hematol Oncol, 25, 336–9.Google Scholar

Imanirad, I., Rajasekhar, A., and Zumberg, M. 2012. A case series of atypical presentations of thrombotic thrombocytopenic purpura. J Clin Apher, 27, 221–6.Google Scholar

Kay, A. C., Solberg, L. A., Nichols, D. A., and Pettit, R. M. 1991. Prognostic significance of computed tomography of the brain in thrombotic thrombocytopenic purpura. Mayo Clin Proc, 66, 602–7.Google Scholar

Kelly, P. J., McDonald, C. T., O’Neill, G., et al. 1998. Middle cerebral artery main stem thrombosis in two siblings with familial thrombotic thrombocytopenic purpura. Neurology, 50, 1157–60.Google Scholar

Kondo, K., Yamawaki, T., Nagatsuka, K., Miyashita, K., and Naritomi, H. 2003. Reversible stenosis of major cerebral arteries demonstrated by MRA in thrombotic thrombocytopenic purpura. J Neurol, 250, 995–7.Google Scholar

Kremer Hovinga, J. A., Vesely, S. K., Terrell, D. R, Lämmle, B., and George, J. N. 2010. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood, 115, 1500–11.Google Scholar

Kremer Hovinga, J. A. and Lämmle, B. 2012. Role of ADAMTS13 in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. Hematol Am Soc Hematol Educ Program 2012, 610–6.Google Scholar

Kroll, M. H., Hellums, J. D., McIntire, L. V., Schafer, A. I., and Moake, J. L. 1996. Platelets and shear stress. Blood, 88, 1525–41.Google Scholar

Kwaan, H. C. 1987. Clinicopathological features of thrombotic thrombocytopenic purpura. Semin Hematol, 24, 74–81.Google Scholar

Kwaan, H. C. and Boggio, L. N. 2005. The clinical spectrum of thrombotic thrombocytopenic purpura. Semin Thromb Hemost, 31, 673–80.Google Scholar

Lämmle, B., Kremer Hovinga, J. A., and Alberio, L. 2005. Thrombotic thrombocytopenic purpura. J Thromb Haemost, 3, 1663–75.Google Scholar

Levy, G. A., Nichols, W. C., Lian, E. C., et al. 2001. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature, 413, 488–94.Google Scholar

Lotta, L. A., Garagiola, I., Palla, R., Cairo, A., and Peyvandi, F. 2010. ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura. Hum Mutat, 31, 11–9.Google Scholar

Lucchesi, A., Fattori, P. P., Ronconi, S., et al. 2015. Atypical presentations of thrombotic thrombocytopenic purpura in middle-aged women with recurrent cerebral macrovascular thrombosis: A case report. Ann Hematol, 94, 1597–8.Google Scholar

Martin, J. N. Jr., Bailey, A. P., Rehberg, J. F., et al. 2008. Thrombotic thrombocytopenic purpura in 166 pregnancies: 1955–2006. Am J Obstet Gynecol, 199, 98–104.Google Scholar

Meloni, G., Proia, A., Antonini, G., et al. 2001. Thrombotic thrombocytopenic purpura: Prospective neurologic neuroimaging and neurophysiologic evaluation. Haematologica, 86, 1194–9.Google Scholar

Moake, J. L. 2002. Thrombotic microangiopathies. N Engl J Med, 347, 589–600.Google Scholar

Moake, J. L. and McPherson, P. D. 1989. Abnormalities of von Willebrand factor multimers in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. Am J Med, 87, 9–15.Google Scholar

Moake, J. L., Rudy, C. K., Troll, J. H., et al. 1982. Unusually large plasma factor VIII: Von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med, 307, 1432–5.Google Scholar

Moschkowitz, E. 1924. Hyaline thrombosis of the terminal arterioles and capillaries: A hitherto undescribed disease. Proc N Y Pathol Soc, 24, 21–4.Google Scholar

Müller, J., Czinyéri, J., Sasvári, I., Garami, M., and Kovács, G. 2001. Thrombotic thrombocytopenic purpura, Moschkowitz syndrome. Int Pediatr, 16, 144–9.Google Scholar

Paliwal, P. R., Teoh, H. L., and Sharma, V. K. 2014. Association between reversible cerebral vasoconstriction syndrome and thrombotic thrombocytopenic purpura. J Neurol Sci, 339, 47–51.Google Scholar

Park, S. A., Lee, T. K., Sung, K. B., and Park, S. K. 2005. Extensive brain stem lesions in thrombotic thrombocytopenic purpura: Repeat magnetic resonance findings. J Neuroimag, 15, 79–81.Google Scholar

Petitt, R. M. 1980. Thrombotic thrombocytopenic purpura: A thirty-year review. Semin Thromb Hemost, 6, 350–5.Google Scholar

Peyvandi, F., Ferrari, S., Lavoretano, S., Canciani, M. T., and Mannucci, P. M. 2004. Von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura. Br J Hematol, 127, 433–9.Google Scholar

Peyvandi, F., Lavoretano, S., Palla, R., et al. 2008. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica, 93, 232–9.Google Scholar

Piastra, M., Currò, V., Chiaretti, A., et al. 2001. Intracranial hemorrhage at the onset of thrombotic thrombocytopenic purpura in an infant: Therapeutic approach and intensive care management. Pediatr Emerg Care, 17, 42–5.Google Scholar

Reese, J. A., Muthurajah, D. S., Kremer Hovinga, J. A., et al. 2013. Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired ADAMTS 13 deficiency: Comparison of incidence, demographic and clinical features. Pediatr Blood Cancer, 60, 1676–82.Google Scholar

Ridolfi, R. L. and Bell, W. R. 1981. Thrombotic thrombocytopenic purpura: A report of 25 cases and a review of the literature. Medicine (Baltimore), 60, 413–28.Google Scholar

Rieger, M., Mannucci, P. M., Kremer Hovinga, J. A., et al. 2005. ADAMTS 13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood, 106, 1262–7.Google Scholar

Rinkel, G. J. E. and Wijdicks, E. F. M. 1991. Stroke in relapsing thrombotic thrombocytopenic purpura. Stroke, 28, 1087–9.Google Scholar

Rock, G. A., Shumak, K. H., Buskard, N. A., et al. 1991. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med, 325, 393–7.Google Scholar

Rock, G., Anderson, D., Clark, W., et al. 2005. Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet. Br J Haematol, 129, 79–86.Google Scholar

Rojas, J.C., Banerjee, C., Siddiqui, F., Nourbakhsh, B., and Powell, C. M. 2013. Acute ischemic stroke caused by atypical thrombotic thrombocytopenic purpura. Neurology, 80, e235–e38.Google Scholar

Ruggeri, Z. M., Dent, J. A., and Saldívar, E. 1999. Contribution of distinct adhesive interactions to platelet aggregation in flowing blood. Blood, 94, 172–8.Google Scholar

Sadler, J. E. 1998. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem, 67, 395–424.Google Scholar

Sadler, J. E., Moake, J. L., Miyata, T., and George, J. M. 2004. Recent advances in thrombotic thrombocytopenic purpura. Hematol Am Soc Hematol Educ Prog, 407–23.Google Scholar

Sarode, R., Gottschall, J. L., Aster, R. H., and McFarland, J. G. 1997. Thrombotic thrombocytopenic purpura: Early and late responders. Am J Hematol, 54, 102–7.Google Scholar

Sarode, R. 2009. Atypical presentations of thrombotic thrombocytopenic purpura: A review. J Clin Apher, 24, 47–52.Google Scholar

Sarode, R., Bandarenko, N., Brecher, M.E., et al. 2014. Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research. J Clin Apher, 29, 148–67.Google Scholar

Sayani, F. A. and Abrams, C. S. 2015. How I treat refractory thrombotic thrombocytopenic purpura. Blood, 125, 3860–67.Google Scholar

Scheid, R., Hegenbart, U., Ballaschke, O., and von Cramon, D. Y. 2004. Major stroke in thrombotic-thrombocytopenic purpura (Moschkowitz syndrome). Cerebrovasc Dis, 18, 83–5.Google Scholar

Scheiflinger, F., Knobl, P., Trattner, B., et al. 2003. Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood, 102, 3241–43.Google Scholar

Scully, M., Yarranton, H., Liesner, R., et al. 2008. Regional UK TTP Registry: Correlation with laboratory ADAMTS 13 analysis and clinical features. Br J Haematol, 142, 819–26.Google Scholar

Scully, M., McDonald, V., Cavenagh, J., et al. 2011. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood, 118, 1746–53.Google Scholar

Scully, M., Hunt, B.J., Benjamin, S., et al. 2012. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol, 158, 323–35.Google Scholar

Scully, M., Thomas, M., Underwood, M., et al. 2014. Thrombotic thrombocytopenic purpura and pregnancy: Presentation, management, and subsequent pregnancy outcomes. Blood, 124, 211–9.Google Scholar

Singer, K., Bornstein, F. P., and Wiles, S. A. 1947. Thrombotic thrombocytopenic purpura. Hemorrhagic diathesis with generalized platelet thrombosis. Blood, 2, 542–54.Google Scholar

Shekman, B. and Einav, Y. 2014. Thrombotic thrombocytopenic purpura and other thrombotic microangiopathic hemolytic anemias: Diagnosis and classification. Autoimmun Rev, 13, 584–6.Google Scholar

Sonneveld, M. A. H., De Maat, M. P. M., and Leebeek, F. W. G. 2014. Von Willebrand factor and ADAMTS13 in arterial thrombosis: A systematic review and meta-analysis. Blood Rev, 28, 167–78.Google Scholar

Sperati, C. J. and Moliterno, A. R. 2015. Thrombotic microangiopathy. Focus on atypical hemolytic uremic syndrome. Hematol Oncol Clin N Am, 29, 541–59.Google Scholar

Studt, J. D., Hovinga, J. A., Radonic, R., et al. 2004. Familial acquired thrombotic thrombocytopenic purpura: ADAMTS 13 inhibitory autoantibodies in identical twins. Blood, 103, 4195–7.Google Scholar

Tardy, B., Page, Y., Convers, P., et al. 1993. Thrombotic thrombocytopenic purpura: MR findings. Am J Neuroradiol, 14, 489–90.Google Scholar

Terrel, D. R., Williams, L. A., Vesely, S. K., et al. 2005. The incidence of thrombotic thrombocytopenic purpura–hemolytic uremic syndrome: All patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost, 3, 1432–6.Google Scholar

Terrell, D. R., Vesely, S. K., Kremer Hovinga, J. A., Lämmle, B., and George, J. N., 2010. Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic–uremic syndromes. Am J Hematol, 85, 844–7.Google Scholar

Tsai, H. M. 1996. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood, 87, 4235–44.Google Scholar

Tsai, H. M. 2000. High titers of inhibitors of von Willebrand factor-cleaving metalloproteinase in a fatal case of acute thrombotic thrombocytopenic purpura. Am J Hematol, 65, 251–5.Google Scholar

Tsai, H. M. 2002. Von Willebrand factor, ADAMTS 13, and thrombotic thrombocytopenic purpura. J Mol Med, 80, 639–47.Google Scholar

Tsai, H. M. 2003. Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. J Am Soc Nephrol, 14, 1072–81.Google Scholar

Tsai, H. M. and Lian, E. C. 1998. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med, 339, 1585–94.Google Scholar

Turner, N., Sartain, S., and Moake, J. 2015. Ultralarge von Willebrand factor-induced platelet clumping and activation of the alternative complement pathway in thrombotic thrombocytopenic purpura and the hemolytic–uremic syndromes. Hematol Oncol Clin North Am, 29, 509–24.Google Scholar

Uğur Bilgin, A., Karaselek, M. A., and Camlı, K. 2014. Successful management of thrombotic thrombocytopenic purpura associated with pregnancy. Transfus Apher Sci, 50, 433–7.Google Scholar

Vesely, S. K. 2015. Life after acquired thrombotic thrombocytopenic purpura: Morbidity, mortality, and risks during pregnancy. J Thromb Haemost, 13 (Suppl. 1): S216–22.Google Scholar

Veyradier, A., Obert, B., Houllier, A., Meyer, D., and Dima, J. P. 2001. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: A study of 111 cases. Blood, 98, 1765–72.Google Scholar

Wada, H., Matsumoto, T., and Yamashita, Y. 2014. Natural history of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Semin Thromb Hemost, 40, 866–73.Google Scholar

Westwood, J. P., Webster, H., McGuckin, S., et al. 2013. Rituximab for thrombotic thrombocytopenic purpura: Benefit of early administration during acute episodes and use of prophylaxis to prevent relapse. J Thromb Haemost, 11, 481–90.Google Scholar

Wijdicks, E. F. M. 1994. Silent brain infarct in thrombotic thrombocytopenic purpura. Stroke, 25, 1297–8.Google Scholar

Willis, M. S. and Bandarenko, N. 2005. Relapse of thrombotic thrombocytopenic purpura: Is it a continuum of disease? Semin Thromb Hemost, 31, 700–8.Google Scholar

Yu, W. L., Leung, T., Soo, Y., Lee, J., and Wong, K. S. 2015. Thrombotic thrombocytopenic purpura with concomitant small- and large-vessel thrombosis, atypical posterior reversible encephalopathy syndrome and cerebral microbleeds. Oxf Med Case Reports, 179–182.Google Scholar

Zheng, X. L. 2015. ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura. Annu Rev Med, 66, 211–25.Google Scholar

Zheng, X. L., Chung, D., Takayama, T. K., et al. 2001. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem, 276, 41059–63.Google Scholar

References

Abend, N. S., Licht, D. J., and Spencer, C. H. (2007). Lupus anticoagulant and thrombosis following Henoch–Schönlein purpura. Pediatr Neurol, 36, 345–7.Google Scholar

Belman, A. L., Leicher, C. R., Moshe, S. L., et al. (1985). Neurologic manifestations of Henoch–Schönlein purpura: Report of three cases and review of the literature. Pediatrics, 75, 687–92.Google Scholar

Berube, M. D., Blais, N., and Lanthier, S. (2014). Neurologic manifestations of Henoch–Schönlein purpura. In Neurologic Aspects of Systemic Disease. Part II. Biller, J. and Ferro, J. M., eds. Amsterdam: Elsevier, pp. 1101–11.Google Scholar

Calvino, M. C., Llorca, J., Garcia-Porrua, C., et al. (2001). Henoch–Schönlein purpura in children from northwest Spain: A 20 year epidemiologic and clinical study. Medicine, 80, 279–90.Google Scholar

Chen, C. L., Chiou, Y. H., Wu, C. Y., Lai, P. H., and Chung, H. M. (2000). Cerebral vasculitis in Henoch–Schönlein purpura: A case report with sequential magnetic resonance imaging changes and treated with plasmapharesis alone. Pediatr Nephrol, 15, 276–8.Google Scholar

Chiaretti, A., Caresta, E., Piastra, M., Pulitano, S., and Di Rocco, C. (2002). Cerebral hemorrhage in Henoch–Schönlein syndrome. Childs Nerv Syst, 18, 365–7.Google Scholar

Chuah, J. and Meaney, T. (2005). Anterior ischaemic optic neuropathy secondary to Henoch–Schönlein purpura. Eye (Lond), 19, 1028.Google Scholar

Clark, J. H. and Fitzgerald, J. F. (1985). Hemorrhagic complications of Henoch–Schönlein syndrome. J Pediatr Gastroenterol Nutr, 4, 311–15.Google Scholar

Elinson, P., Foster, K. W., and Kaufman, D. B. (1990). Case report: Magnetic resonance imaging of central system vasculitis. Acta Paediatr Scand, 70, 710–3.Google Scholar

Eun, S. H., Kim, S. J., Cho, D. S., et al. (2003). Cerebral vasculitis in Henoch–Schönlein purpura: MRI and MRA findings, treated with plasmapheresis alone. Pediatr Int, 45, 484–7.Google Scholar

Garzoni, L., Vanoni, F., Rizzi, M., et al. (2009). Nervous system dysfunction in Henoch–Schönlein syndrome: Systematic review of the literature. Rheumatology, 48, 1524–9.Google Scholar

Giangiacomo, J. and Tsai, C. C. (1977). Dermal and glomerular deposition of IgA in anaphylactoid purpura. Am J Dis Child, 131, 981–3.Google Scholar

Ha, T. S. and Cha, S. H. (1996). Cerebral vasculitis in Henoch–Schönlein purpura: A case report with sequential magnetic resonance imaging. Pediatr Nephrol, 10, 634–6.Google Scholar

Heberden, W. (1801). Commentari Di Morborium Historia et Curatione. London: Payne. Reprinted as “Commentaries on the history and cure of diseases,” in The Classics of Medicine Library, Birmingham, AL: Gryphon Editions Ltd, 1982, 395–7.Google Scholar

Henoch, E. H. (1874). Über eine eigenthumliche Form von Purpura. Berlin Klin Wochenschr, 11, 641–3.Google Scholar

Henoch, E. H. (1899). Vorlesungen über Kinderkrankheiten. In Volhesunger über Kinderkrankheiten, Hirschward, A., ed. Berlin: Aufli, p. 839.Google Scholar

Knight, J. F., Harada, T., Thomas, M. A. B., et al. (1988). IgA rheumatoid factor and other autoantibodies in acute Henoch–Schönlein purpura. Contrib Nephrol, 67, 117–20.Google Scholar

Levy, M., Broyer, M., Arsan, A., Levy-Bentolila, D., and Habib, R. (1976). Anaphylactoid purpura nephritis in childhood: Natural history and immunopathology. Adv Nephrol, 6, 183–228.Google Scholar

Ng, C. C., Hunag, S. C., Huang, L. T. (1996) Henoch–Schönlein purpura with intracerebral hemorrhage, case report. Pediatr Radiol, 26, 276–7.Google Scholar

Osler, W. (1914). The visceral lesions of purpura and allied conditions. Br Med J Clin Res, 1, 517–25.Google Scholar

Paolini, S., Ciappetta, P., Piattella, M. C., and Domenicucci, M. (2003). Henoch– Schönlein syndrome and cerebellar hemorrhage: Report of an adolescent case and literature review. Surg Neurol, 60, 339–42.Google Scholar

Saulsbury, F. T. (1999). Henoch–Schönlein purpura in children: Report of 100 patients and review of the literature. Medicine (Baltimore), 78, 395–409.Google Scholar

Saulsbury, F. T. (2007). Clinical update: Henoch–Schönlein purpura. Lancet, 369, 976–8.Google Scholar

Scattarella, V., Pannarale, R., D’Angelo, V., et al. (1983). Occipital hemorrhage in a child with Henoch–Schönlein syndrome. J Neurosurg Sci, 27, 37–9.Google Scholar

Schönlein, J. L. (1832). In Allgemeine und Spezielle Pathologie und Therapie. Würzburg: C. Etlinger, vol. 2, pp. 68–70.Google Scholar

Shin, J., Lee, J. S., Kim, H. D., and Lee, Y. M. (2006). Neurologic manifestations and treatment of Henoch–Schönlein purpura. Brain Dev, 28, 547.Google Scholar

Sokol, D. K., McIntyre, J. A., Short, R. A., et al. (2000). Henoch–Schönlein purpura and stroke: Antiphosphatidyl-ethanolamine antibody in CSF and serum. Neurology, 55, 1379–81.Google Scholar

Stevenson, J. A., Leong, L. A., Cohen, A. H., and Border, W. A. (1982). Simultaneous demonstration of IgA deposits in involved skin, intestine, and kidney. Arch Pathol Lab Med, 106, 192–5.Google Scholar

Trapani, S., Miceli, A., Grisolia, F., et al. (2005). Henoch–Schönlein purpura in childhood: Epidemiological and clinical analysis of 150 cases over a 5-year period and review of the literature. Semin Arthritis Rheum, 35, 143–53.Google Scholar

Wen, Y.-K., Yang, Y., and Chang, C.-C. (2005). Cerebral vasculitis and intracerebral hemorrhage in Henoch–Schönlein purpura treated with plasmapheresis. Pediatr Nephrol, 20, 223–5.Google Scholar

Woolfenden, A. R., Hukin, J., Poskitt, K. J., et al. (1998). Encephalopathy complicating Henoch–Schönlein purpura; reversible MRI changes. Pediatr Neurol, 19, 74–7.Google Scholar

Wu, T. T., Sheu, S. J., and Chou, L. C. (2002). Henoch–Schönlein purpura with bilateral central retinal artery occlusion. Br J Ophthalmol, 86, 351–2.Google Scholar

Yilmaz, C., Caksen, H., Arslan, S., et al. (2006). Bilateral brachial plexopathy complicating Henoch–Schönlein purpura. Brain Dev, 28, 326–8.Google Scholar

Book contents

Section 5 - Disorders Involving Abnormal Coagulation

Summary

Access options

References

References

References

References

References

References

References

Save book to Kindle

Save book to Dropbox

Save book to Google Drive